Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma

International Journal of Cancer

Volumn 130, Issue 10, 2012, Pages 2455-2463

  Altanerova, Veronika ^a,b   Cihova, Marina ^a   Babic, Michal ^c   Rychly, Boris ^d   Ondicova, Katarina ^e   Mravec, Boris ^e,f   Altaner, Cestmir ^a,b  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b St Elisabeth Cancer Institute   (Slovakia)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^d Cytopathos Ltd   (Slovakia)

^e Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^f INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

CDy::UPRT; continuous intracerebro ventricular 5 FC delivery; glioblastoma; mesenchymal stem cells; suicide gene therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE URACIL PHOSPHORIBOSYLTRANSFERASE; FLUCYTOSINE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL BASED GENE THERAPY; CONTROLLED STUDY; DNA MODIFICATION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME PRODRUG THERAPY; FEASIBILITY STUDY; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SIMULATION; SUICIDE GENE THERAPY; SURVIVAL TIME; THERAPY DELAY;

ADIPOSE TISSUE; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; FEASIBILITY STUDIES; FLUCYTOSINE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GLIOBLASTOMA; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; PENTOSYLTRANSFERASES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; YEASTS;

EID: 84859111006     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26278     Document Type: Article

References (46)

1. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG,. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165-80. (Pubitemid 43261763)
2. Charles N, Holland EC,. The perivascular niche microenvironment in brain tumor progression. Cell Cycle 2010; 9: 3012-21.
3. Becher OJ, Hambardzumyan D, Fomchenko EI, Momota H, Mainwaring L, Bleau AM, Katz AM, Edgar M, Kenney AM, Cordon-Cardo C, Blasberg RG, Holland EC,. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 2008; 68: 2241-9. (Pubitemid 351521797)
4. Soltysova A, Altanerova V, Altaner C,. Cancer stem cells. Minireview. Neoplasma 2005; 52: 435-40.
5. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C,. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67: 6304-13. (Pubitemid 47037513)
6. Altaner C,. Prodrug cancer gene therapy. Cancer Lett 2008; 270: 191-201.
7. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S, Bengzon J,. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 2009; 17: 183-190.
8. Le Blanc K,. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5: 485-9. (Pubitemid 38028708)
9. Koppula PR, Chelluri LK, Polisetti N, Vemuganti GK,. Histocompatibility testing of cultivated human bone marrow stromal cells-a promising step towards pre-clinical screening for allogeneic stem cell therapy. Cell Immunol 2009; 259: 61-5.
10. Griffin MD, Ritter T, Mahon BP,. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 2010; 21: 1641-55.
11. Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V, Altaner C,. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 2008; 10: 1071-82.
12. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C,. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 2010; 18: 223-31.
13. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY,. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97: 12846-51.
14. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, Galli R, Selleri S, Di Meco F, De Fraja C, Vescovi A, Cattaneo E, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000; 6: 447-50. (Pubitemid 30208163)
15. Aboody KS, Najbauer J, Schmidt NO, Yang W, Wu JK, Zhuge Y, Przylecki W, Carroll R, Black PM, Perides G,. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-oncology 2006; 8: 119-26. (Pubitemid 46542656)
16. Aboody KS, Najbauer J, Danks MK,. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008; 15: 739-52. (Pubitemid 351627357)
17. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC,. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002; 174: 11-20. (Pubitemid 34218904)
18. Au P, Tam J, Fukumura D, Jain RK,. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 2008; 111: 4551-58.
19. Kondo T, Setoguchi T, Taga T,. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101: 781-86. (Pubitemid 38121035)
20. Zheng X, Shen G, Yang X, Liu W,. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2007; 67: 3691-97. (Pubitemid 46762154)
21. Zhou XD, Wang XY, Qu FJ, Zhong YH, Lu XD, Zhao P, Wang DH, Huang QB, Zhang L, Li XG,. Detection of cancer stem cells from the C6 glioma cell line. J Int Med Res 2009; 37: 503-10.
22. Babic M, Horák D, Trchová M, Jendelová P, Glogarová K, Lesný P, Herynek V, Hájek M, Syková E,. Poly(L -lysine)-modified iron oxide nanoparticles for stem cell labelling. Bioconjug Chem 2008; 19: 740-50. (Pubitemid 351431406)
23. Paxinos G, Watson C,. The rat brain in stereotaxic coordinates. New York: Academic Press, 1997. 256 p.
24. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA,. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-26. (Pubitemid 23304389)
25. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE,. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995; 55: 4808-12.
26. Dawborn JK, Page MD, Schiavone DJ,. Use of 5-fluorocytosine in patients with impaired renal function. Br Med J 1997; 4: 382-84.
27. Matuskova M, Hlubinova K, Pastorakova A, Hunakova L, Altanerova V, Altaner C, Kucerova L,. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 2010; 290: 58-67.
28. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS,. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002; 62: 5657-63. (Pubitemid 35204717)
29. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, Yu JS,. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002; 62: 7170-4. (Pubitemid 36025232)
30. Bexell D, Scheding S, Bengzon J,. Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 2010; 18: 1067-75.
31. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S, Bengzon J,. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 2009; 17: 183-90.
32. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-13.
33. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC,. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002; 174: 11-20. (Pubitemid 34218904)
34. Schaffler A, Buchler C,. Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 2007; 25: 818-26.
35. Chang DY, Yoo SW, Hong Y, Kim S, Kim SJ, Yoon SH, Cho KG, Paek SH, Lee YD, Kim SS, Suh-Kim H,. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010; 127: 1975-83.
36. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, Cao W, Han C, Chen Y,. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006; 80 267-74.
37. Hall B, Andreeff M, Marini F,. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007; 180: 263-83.
38. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C,. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010; 9: 129.
39. Ohlsson LB, Varas L, Kjellman C, Edvardsen K, Lindvall M,. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatine matrix. Exp Mol Pathol 2003; 75: 248-55. (Pubitemid 37373711)
40. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203: 1235-47. (Pubitemid 43736593)
41. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D,. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-95. (Pubitemid 36554699)
42. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82. (Pubitemid 46054518)
43. Bexell D, Gunnarsson S, Siesjö P, Bengzon J, Darabi A,. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. Int J Cancer 2009; 125: 15-22.
44. Shi DZ, Hu WX, Li LX, Chen G, Wei D, Gu PY,. Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma. Chin Med J (Engl) 2009 122: 1267-72.
45. Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH, Park IH, Black PM, Carroll RS, Lee J, Kim SK,. Targeting rat brain stem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 2009; 15: 4925-34.
46. Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY, Jung HW, Lee DH, Kim SK,. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol 2011; 13: 61-9.